Relapsing-remitting multiple sclerosis
Drug research and approvals for relapsing-remitting multiple sclerosis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 56 studies of relapsing-remitting multiple sclerosis are recruiting on ClinicalTrials.gov, Health Canada has authorized 11 drug trials for it since 2013, FDA has 4 approved and 0 open orphan designations naming it, and the EU has 2 authorised medicines for it.
- Recruiting worldwide: 56
- Trials authorized in Canada: 11
- FDA orphan approvals: 4
- EU medicines: 2
- A Study of IMS001 in Patients With Multiple SclerosisNCT07935031 · Phase 1 · Zhuhai Hengqin ImStem Biotechnology Co., Ltd. · starts Sep 28, 2026
- REAL-MS: Observational Database Study of AHSCT and MS TherapiesNCT07899502 · Not reported · Imperial College London · starts Oct 7, 2026
- Early Versus Delayed Start of Ocrevus Zunovo for Relapsing Multiple SclerosisNCT07878923 · Not reported · Oklahoma Medical Research Foundation · starts Sep 30, 2026
- Non-interventional Study of Subcutaneous Ocrelizumab in Persons With Relapsing-Remitting Multiple SclerosisNCT07827586 · Not reported · Hoffmann-La Roche · starts Sep 23, 2026
- A Study to Evaluate the Preliminary Efficacy and Safety of Terfenadine in Patients With Relapsing-Remitting Multiple…NCT07827716 · Phase 2 · Chuan Qin · starts Aug 15, 2026
- A Study of Rocbrutinib in PRL-Positive Relapsing-Remitting Multiple SclerosisNCT07776743 · Phase 2 · Guangzhou Lupeng Pharmaceutical Company LTD. · starts Aug 1, 2026
- Brain Imaging and Immune Changes During Remibrutinib Treatment in Multiple Sclerosis.NCT07758270 · Not reported · Washington University School of Medicine · starts Aug 15, 2026
- Relationship Between Single- and Dual-Task Obstacle Crossing Performance and Fatigue and Disability in Multiple…NCT07736482 · Not reported · Afyonkarahisar Health Sciences University · starts Mar 20, 2026
- Healthy Eating and Active Living for People Living With Multiple Sclerosis (HEAL MS): A Lifestyle Program for People…NCT07589062 · Not applicable · New York University Abu Dhabi · starts Apr 15, 2026
Approved 12
- Dimethyl fumarateKelch-like ECH-associated protein 1 inhibitor
- NatalizumabIntegrin alpha-4/beta-7 inhibitor
- OcrelizumabB-lymphocyte antigen CD20 binding agent
- DaclizumabInterleukin-2 receptor inhibitor
- FingolimodSphingosine 1-phosphate receptor agonist
- SiponimodSphingosine 1-phosphate receptor Edg-1 agonist
- Diroximel fumarateKelch-like ECH-associated protein 1 inhibitor
- OfatumumabB-lymphocyte antigen CD20 binding agent
- UblituximabB-lymphocyte antigen CD20 binding agent
- OzanimodSphingosine 1-phosphate receptor Edg-1 modulator
- TeriflunomideDihydroorotate dehydrogenase inhibitor
- PonesimodSphingosine 1-phosphate receptor Edg-1 agonist
Phase 3 12 of 29
- Interferon beta-1aInterferon alpha/beta receptor agonist
- Glatiramer acetate
- Interferon beta-1bInterferon alpha/beta receptor agonist
- AlemtuzumabCAMPATH-1 antigen inhibitor
- RituximabB-lymphocyte antigen CD20 binding agent
- Peginterferon beta-1aInterferon alpha/beta receptor agonist
- SimvastatinHMG-CoA reductase inhibitor
- EvobrutinibTyrosine-protein kinase BTK inhibitor
- Influenza virus vaccineBiological vaccine - induces immune response
- Laquinimod
- CladribineDNA inhibitor
- Human immunoglobulin gReplacement therapy, immunomodulatory effects
Phase 2 12 of 36
- AmiselimodSphingosine 1-phosphate receptor modulator
- AtorvastatinHMG-CoA reductase inhibitor
- AbataceptT-lymphocyte activation antigen CD86 inhibitor
- VatelizumabIntegrin alpha-2 antagonist
- MelatoninMelatonin receptor agonist
- EstriolEstrogen receptor modulator
- TemelimabSyncytin-1 inhibitor
- CytarabineDNA inhibitor
- LamotrigineSodium channel alpha subunit blocker
- MitoxantroneDNA topoisomerase II alpha inhibitor
- Flupirtine
- ClemastineHistamine H1 receptor antagonist
Phase 1 or earlier 12 of 18
- Monomethyl fumarateKelch-like ECH-associated protein 1 inhibitor
- GSK-2018682
- MethylphenidateDopamine transporter inhibitor
- PioglitazonePeroxisome proliferator-activated receptor gamma agonist
- SirolimusFK506-binding protein 1A inhibitor
- LiothyronineThyroid hormone receptor agonist
- Insulin humanInsulin receptor agonist
- Insulin porkInsulin receptor agonist
- Dexamethasone phosphoric acidGlucocorticoid receptor agonist
- GuanabenzAdrenergic receptor alpha-2 agonist
- TetracyclineBacterial 70S ribosome inhibitor
- FirategrastIntegrin alpha-4/beta-1 antagonist
How its trials ended
563 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 187 whose ending is known, 47% met their primary endpoint, 9% missed it and 45% stopped early.
- Completed, result not reported23241%
- Ongoing9517%
- Met its primary endpoint8715%
- Status unknown499%
- Stopped: other or unclear407%
- Stopped: enrollment or feasibility193%
- Missed its primary endpoint163%
- Stopped: sponsor or business decision132%
- Stopped: lack of efficacy81%
- Stopped: funding41%
| Nov 29, 2024 | A randomized, double-blind, parallel-group study to compare pharmacokinetics, pharmacodynamics, clinical effects, and safety between abp 692 and ocrevus®…Abp 692 | Amgen | Ongoing |
| Dec 29, 2021 | A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib versus teriflunomide in participants with…Remibrutinib (LOU064) / Teriflunomide | Novartis Pharmaceuticals | Ongoing |
| Oct 15, 2018 | An open-label, single arm, multi-center extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with relapsing…Ofatumumab (OMB157) | Novartis Pharmaceuticals | Ongoing |
| Oct 11, 2018 | A randomized, controlled, open-label, rater-blinded, phase 3b study of the efficacy, safety, and tolerability of 6-week extended interval dosing of natalizumab…Tysabri (natalizumab) | Biogen | Closed |
| Jan 26, 2017 | An open-label, single-arm study to evaluate the effectiveness and safety of ocrelizumab in patients with early stage relapsing remitting multiple sclerosisRO4964913 (ocrelizumab) | Roche | Ongoing |
| Dec 16, 2016 | A phase 3b, 12-month, open-label, multicenter study to evaluate the efficacy and safety of BIIB019, daclizumab, in subjects with relapsing-remitting multiple…Daclizumab | Biogen | Ongoing |
| Mar 30, 2016 | A phase 3 open label study to evaluate the long-term safety and tolerability of alks 8700 in adults with relapsing remitting multiple sclerosisAlks 8700 | Alkermes | Closed |
| Oct 8, 2015 | An open-label study to assess the effects of BG00012 on lymphocyte subsets in subjects with relapsing-remitting multiple sclerosisTecfidera (dimethyl fumarate, BG00012) | Biogen | Closed |
| Aug 5, 2015 | Open-label, randomized, multicenter, multiple-dose, active-controlled, parallel-group, efficacy and safety study of BG00012 in children from 10 to less than 18…Dimethyl fumarate/ Interferon BETA-1A | Biogen | Closed |
| Mar 4, 2015 | Randomized, controlled pilot trial of domperidone in relapsing-remitting multiple sclerosis (MS)Domperidone | University of Calgary | Closed |
| Oct 13, 2000 | NovantroneReducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive… | Serono, Inc. | Approved |
| Oct 13, 2000 | NovantroneReducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive… | Serono, Inc. | Approved |
| Dec 20, 1996 | CopaxoneFor reduction of the frequency of relapses in patients with relapsing-remitting multiple sclerosis. | Teva Pharmaceuticals USA | Approved |
| Jul 23, 1993 | BetaseronIn ambulatory patients with relapsing-remitting multiple sclerosis to reduce the frequency of clinical exacerbations. | Chiron Corp. & Berlex Laboratories | Approved |
| May 20, 2020 | ZeposiaOzanimod | Bristol-Myers Squibb Pharma EEIG | EMA ↗ |
| Sep 12, 2013 | LemtradaAlemtuzumab | Sanofi Belgium | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA